Verastem Appoints Matthew Ros as COO Ahead of Key Therapy Launch in 2025

Verastem Oncology Strengthens Leadership with New COO Appointment

Verastem Oncology, a biopharmaceutical company focused on developing treatments for RAS/MAPK pathway-driven cancers, appoints Matthew E. Ros as its new Chief Operating Officer. This strategic decision comes at a crucial time as the company prepares for the anticipated mid-2025 launch of its investigational combination therapy for recurrent KRAS mutant low-grade serous ovarian cancer (LGSOC). This rare cancer currently lacks approved treatment options, making Verastem's potential first-in-class therapy a significant development in the field. Ros joins the executive leadership team, reporting directly to CEO Dan Paterson, and brings over 35 years of extensive experience in the biopharmaceutical sector.

Ros has held prominent positions at several leading biopharmaceutical firms, including serving as CEO of FORE Biotherapeutics and holding significant roles at Epizyme, Sanofi-Genzyme, and ARIAD Pharmaceuticals. His deep expertise in commercialization and operational excellence is expected to play a vital role in Verastem's transition to a commercial-stage entity. Paterson expresses confidence in Ros's ability to drive the company's operational strategy forward, especially as it seeks to navigate the complexities of launching a new therapy amidst regulatory scrutiny and competitive pressures.

In addition to his corporate accomplishments, Ros has a notable history at Bristol-Myers Squibb, where he was instrumental in launching key oncology products. His track record in building commercial organizations and securing FDA approvals aligns with Verastem’s mission to enhance treatment options for patients with complex cancer conditions. Ros's appointment signals Verastem's commitment to strengthening its operational capabilities as it gears up for a significant product launch and aims to establish itself as a leader in the oncology market.

Verastem also recently announced a $150 million credit facility and a $7.5 million equity investment from Oberland Capital Management LLC. This funding aims to support its collaboration with IQVIA Inc. to optimize the launch of its investigational therapy, potentially providing much-needed resources for commercial revenue generation. The company is preparing for a Prescription Drug User Fee Act (PDUFA) action date set for June 30, 2025, which will be a critical milestone for Verastem in gaining FDA approval.

With the combination of strategic funding and the addition of a seasoned executive like Ros, Verastem Oncology appears well-positioned to advance its mission of delivering innovative cancer therapies and navigating the challenges of the competitive biopharmaceutical landscape.